Fidelta focuses on drug discovery in infection and inflammation

Fidelta’s Managing Director, Adrijana Vinter, speaks at BIO-Europe® 2019 in Hamburg about her company’s excellence in integrated drug discovery services, from target validation to early preclinical development. The CRO is able to be more selective than some since it is smaller, and has chosen to focus on two major therapeutic areas, infection and inflammation. It has also participated in 75 integrated projects in seven years, with six molecules successfully going to the clinic. Current plans include investing further in translational science.

Adrijana Vinter,Fidelta,BIO-Europe,pharma,biotech,partnering,drug development,drug discovery,CRO,partnering conference,drug discovery services,therapeutic areas,infection,infalmation,translational science,